Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Other Comprehensive Income
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		$ (187)	$ 79	$ (302)	$ (302)
Other Comprehensive Income | Net Investment Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	0	0	0	(21)
Financial expenses [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		241	117	805	565
Financial expenses [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	$ 0	$ 0	$ 0	$ (2)

[1] In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva’s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3 million.